

## Nogo Receptor/RTN4R Protein, Mouse, Recombinant (His)

### General Information

Synonyms:	Rtn4r;NgR;NgR1;reticulon 4 receptor;NOGOR
Protein Construction:	Cys27-Ser447
Species:	Mouse
Expression Host:	HEK293 Cells
Accession:	Q99PI8
Molecular Weight:	46.7 kDa (Predicted); 60-70 kDa (Due to glycosylation)

### QC Testing

Biological Activity:	Activity testing is not tested. It is theoretically active, but we cannot guarantee it.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

NOGO Receptor 1 (RTN4R) regulates axonal growth, as well as axon regeneration after injury. The gene maps to the 22q11.2 schizophrenia susceptibility locus and is thus a strong functional and positional candidate gene. RTN4R may modulate the genetic risk or clinical expression of schizophrenia in a subset of patients and identify additional studies that will be necessary to clarify the role of RTN4R in psychiatric phenotypes.

Reference

Wang, X. et al., 2006, Ann Neurol. 60(5): 540-549.2.

Wang, Y.Z. et al., 2006, Neuroreport.17(6):605-609.3.

Zhu, H.Y. et al., 2007, Hum Pathol. 38(3): 426-434.4.

David, S. et al., 2008, Trends Neurosci. 31(5): 221-226.5.

Jiang, W. et al., 2009, Transl Res. 154(1): 40-48.6.

Zhang, L. et al., 2009, J Neurosci, 9(19): 6348-6352.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286

E\_mail:info@targetmol.com

Address:34 Washington Street,Wellesley Hills,MA 02481